| Literature DB >> 26907316 |
Alessandra Buja1, Giuliana Solinas2, Modesta Visca3, Bruno Federico4, Rosa Gini5, Vincenzo Baldo6, Paolo Francesconi7, Gino Sartor8, Mariadonata Bellentani9, Gianfranco Damiani10.
Abstract
Interest in chronic conditions reflects their role as the first cause of death and disability in developed countries; improving the management of these conditions is a priority for health care services. The aim of this study was to establish which sociodemographic factors influence adherence to standards of care for chronic heart failure (CHF). A generalized multilevel structural equation model was developed and applied to a sample of patients with CHF obtained from administrative data flows in six Italian regions to ascertain any associations between adherence to standards of care for CHF and sociodemographic variables. Indicators of compliance were adherence to beta-blocker therapy (BB-A) and Angiotensin Convertin Enzime inhibitor/Angiotensin Receptor Blocker therapy (ACE-A), and creatinine and electrolyte testing (CNK-T). All indicators were computed over a one-year follow-up. Among a cohort of 24,997 patients, the BB-A rate was 40.4%, the ACE-A rate 61.1%, and the CNK-T rate 57.0%. Factors found associated with adherence were gender, age, and citizenship. Our study shows an inadequate adherence to standards of care for CHF, particularly associated with certain sociodemographic characteristics. This suggests the need to improve the role of primary care in managing this chronic condition. The measures considered only apply to patients with a reduced Left Ventricular Ejection Fraction, hence a limitation of this analysis is the lack of information on left ventricular ejection.Entities:
Keywords: health care research; inequalities; primary health care; quality of care
Mesh:
Year: 2016 PMID: 26907316 PMCID: PMC4772258 DOI: 10.3390/ijerph13020238
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Characteristics of the sample.
| Variable | Modality | Absolute Frequency | % Relative Frequency |
|---|---|---|---|
| Gender | Men | 12,394 | 49.58 |
| Women | 12,603 | 50.42 | |
| Age | 16–44 | 303 | 1.21 |
| 45–64 | 2765 | 11.06 | |
| 65–74 | 4891 | 19.57 | |
| 75–84 | 9442 | 37.77 | |
| 85+ | 7596 | 30.39 | |
| Nationality | Italian | 23,606 | 94.45 |
| HMPC 1 | 1391 | 5.55 | |
| Charlson index | No comorbidity | 6705 | 26.82 |
| Low comorbidity | 6267 | 25.07 | |
| High comorbidity | 12,025 | 48.11 | |
| Time since diagnosis | <3 years | 10,592 | 42.37 |
| >3 years | 14,405 | 57.63 |
1 High-Migratory-Pressure Countries.
Bivariate association (chi-squared test) between adherence to standards of care and sociodemographic characteristics.
| Variable | ACE-A | BB-A | CNK-T | ||||
|---|---|---|---|---|---|---|---|
| Gender | Men | 7927 (63.96%) | 0.000 | 5610 (45.26%) | 0.000 | 6985 (56.36%) | 0.000 |
| Women | 7337 (58.22%) | 4497 (35.68%) | 7273 (57.71%) | ||||
| Age | 16–44 | 110 (36.3%) | 0.000 | 116 (38.28%) | 130 (42.90%) | 0.000 | |
| 45–64 | 1788 (64.67%) | 1541 (55.73%) | 1340 (48.46%) | ||||
| 65–74 | 3363 (68.76%) | 2510 (51.32%) | 0.000 | 2821 (57.68%) | |||
| 75–84 | 6099 (64.59%) | 3924 (41.56%) | 5731 (60.70%) | ||||
| 85+ | 3904 (51.4%) | 2016 (26.54%) | 4236 (55.77%) | ||||
| Nationality | Italians | 14,530 (51.55%) | 0.000 | 9640 (40.84%) | 0.540 | 13,500 (57.19%) | 0.000 |
| HMPC | 86 (43.22%) | 77 (38.69%) | 86 (43.22%) | ||||
| Charlson index | No comorbidity | 4215 (62.86%) | 0.000 | 2494 (37.20%) | 3322 (49.55%) | 0.000 | |
| Low Comorbidity | 4038 (64.43%) | 2702 (43.11%) | 0.000 | 3576 (57.06%) | |||
| High Comorbidity | 7011 (58.30%) | 4911 (40.84%) | 7360 (61.21%) | ||||
| Time since diagnosis | <3 years | 6376 (60.20%) | 0.016 | 4137 (39.06%) | 0.000 | 5763 (54.41%) | 0.000 |
| >3 years | 8888 (61.70%) | 5970 (41.44%) | 8495 (58.97%) | ||||
Figure 1Prevalence of CHF (mainly stage III–IV NYHA) with 95% CI. HMPC: High-Migratory-Pressure Countries.
Results of the multilevel structural equation model with adherence as a latent variable; 95% confidence intervals (CI), odds ratios and p-values for adherence to process indicators.
| Indicator | Variable | Modality | OR | 95% CI | ||
|---|---|---|---|---|---|---|
| 95% UL | 95% LL | |||||
| ACE-A | Gender (ref. Men) | Women | 0.86 | 0.82 | 0.91 | <0.001 |
| Age (ref. 65–74 years) | 16–44 | 0.26 | 0.20 | 0.34 | <0.001 | |
| 45–64 | 0.81 | 0.73 | 0.90 | <0.001 | ||
| 75–84 | 0.84 | 0.78 | 0.91 | <0.001 | ||
| 85+ | 0.49 | 0.46 | 0.54 | <0.001 | ||
| Nationality (ref. Italians) | HMPC | 0.47 | 0.35 | 0.63 | <0.001 | |
| Charlson Index (ref. No/low comorbidity) | high comorbidity | 0.85 | 0.81 | 0.88 | <0.001 | |
| Time since diagnosis (ref. >3 years) | ≤3 years | 1.21 | 1.14 | 1.29 | <0.001 | |
| BB-A | Gender (ref. Men) | Women | 0.83 | 0.79 | 0.88 | <0.001 |
| Age (ref. 65–74 years) | 16–44 | 0.64 | 0.50 | 0.82 | <0.001 | |
| 45–64 | 1.21 | 1.09 | 1.33 | <0.001 | ||
| 75–84 | 0.69 | 0.64 | 0.74 | <0.001 | ||
| 85+ | 0.36 | 0.33 | 0.39 | <0.001 | ||
| Nationality (ref. Italians) | HMPC | 0.67 | 0.50 | 0.90 | 0.008 | |
| Charlson Index (ref. No/low comorbidity) | high comorbidity | 1.08 | 1.04 | 1.12 | <0.001 | |
| Time since diagnosis (ref. >3 years) | ≤3 years | 1.04 | 0.97 | 1.10 | 0.270 | |
| CNK-T | Gender (ref. Men) | Women | 1.06 | 1.01 | 1.13 | 0.029 |
| Age (ref. 65–74 years) | 16–44 | 0.63 | 0.49 | 0.81 | <0.001 | |
| 45–64 | 0.71 | 0.65 | 0.79 | <0.001 | ||
| 75–84 | 1.11 | 1.03 | 1.20 | 0.007 | ||
| 85+ | 0.90 | 0.83 | 0.98 | 0.010 | ||
| Nationality (ref Italians) | HMPC | 0.66 | 0.49 | 0.90 | 0.007 | |
| Charlson Index (ref. No/low comorbidity) | high comorbidity | 1.30 | 1.25 | 1.34 | <0.001 | |
| Time since diagnosis (ref. >3 years) | ≤3 years | 0.96 | 0.90 | 1.02 | 0.223 | |
Figure 2Multilevel structural equation model (SEM) with estimates of the parameters expressed as exponential functions of the regression coefficients (odds ratios). Direct effects are represented. Dashed grey lines stand for non-significant odds ratio paths, solid lines for significant odds ratio paths. (ACE-A = Therapy with ace-inhibitors or angiotensin-receptor blockers; BB-A = Therapy with Beta-Blockers; CNK-T = Creatinine, Sodium and Potassium Test).